ICREC Research Program, Germans Trias i Pujol Health Research Institute, Badalona, Spain.
Center of Regenerative Medicine in Barcelona, Barcelona, Spain.
Stem Cell Res Ther. 2017 Oct 27;8(1):238. doi: 10.1186/s13287-017-0695-y.
For years, sufficient progress has been made in treating heart failure following myocardial infarction; however, the social and economic burdens and the costs to world health systems remain high. Moreover, treatment advances have not resolved the underlying problem of functional heart tissue loss. In this field of research, for years we have actively explored innovative biotherapies for cardiac repair. Here, we present a general, critical overview of our experience in using mesenchymal stem cells, derived from cardiac adipose tissue and umbilical cord blood, in a variety of cell therapy and tissue engineering approaches. We also include the latest advances and future challenges, including good manufacturing practice and regulatory issues. Finally, we evaluate whether recent approaches hold potential for reliable translation to clinical trials.
多年来，在治疗心肌梗死后心力衰竭方面已经取得了足够的进展；然而，社会和经济负担以及对世界卫生系统的成本仍然很高。此外，治疗进展并未解决功能心脏组织损失的根本问题。在这个研究领域，多年来我们一直在积极探索心脏修复的创新生物疗法。在这里，我们对我们使用源自心脏脂肪组织和脐带血的间充质干细胞的各种细胞治疗和组织工程方法的经验进行了全面、批判性的概述。我们还包括最新进展和未来挑战，包括良好生产规范和监管问题。最后，我们评估了最近的方法是否有可能可靠地转化为临床试验。
